Global Health Issues

FDA Authorizes Essilor’s Stellest Lens, First U.S. Spectacle Lens Shown to Slow Childhood Myopia

The De Novo authorization follows a U.S. randomized trial reporting a 71% average slowing of pediatric myopia over two years.